PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29703045
OWN - NLM
STAT- MEDLINE
DCOM- 20180507
LR  - 20180516
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 17
DP  - 2018 Apr
TI  - A feasibility and safety study of concurrent chemotherapy based on genetic
      testing in patients with high-risk salivary gland tumors: Preliminary results.
PG  - e0564
LID - 10.1097/MD.0000000000010564 [doi]
AB  - BACKGROUND: This prospective study was conducted to evaluate the feasibility and 
      safety of customized chemotherapy regimens based on the gene characteristics of
      salivary gland tumors. METHODS: Patients were enrolled with histologically
      confirmed intermediate or high grade, stage T3-4, N1-3 disease, and T1-2, N0
      patients with a close (</=1 mm) or microscopically positive surgical margin were 
      also enrolled in the study. All patients received radical surgery and
      postoperative concurrent chemoradiotherapy. To evaluate the responsiveness of
      therapies, the chemotherapy regimen was based on gene targets, beta-tubulin III, 
      ABCB1, STMN1, and CYP1B1 (for docetaxel) and TYMS (for pemetrexed). The primary
      endpoints were treatment compliance and acute toxicities. RESULTS: A total of 20 
      patients were enrolled between September 2013 and January 2016. The median age
      was 46 years (range: 23-70 years). Genetic testing showed that 8 patients may
      have been sensitive to docetaxel, 5 patients may have been sensitive to
      pemetrexed, and 7 patients sensitive to either docetaxel or pemetrexed. All
      patients received the full dose of radiation. A total of 19 patients (95%)
      completed 2 cycles of concurrent chemotherapy (CCT). One patient treated
      concurrently with pemetrexed experienced grade 3 neutropenia. Three patients
      experienced grade 3 oral mucositis, and 2 patients experienced grade 3
      dermatitis. CONCLUSION: Our study demonstrated that a CCT selecting method based 
      on the gene targets associated with drug sensitivity was clinically feasible and 
      safe. Further studies enrolled more patients with longer follow-up times are
      needed to confirm the clinical efficacy of this CCT selecting method.
FAU - Li, Rongrong
AU  - Li R
AD  - Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People's Hospital,
      Shanghai Jiao Tong University, School of Medicine, Shanghai, P.R. China.
FAU - Dou, Shengjin
AU  - Dou S
FAU - Ruan, Min
AU  - Ruan M
FAU - Zhang, Chenping
AU  - Zhang C
FAU - Zhu, Guopei
AU  - Zhu G
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (ABCB1 protein, human)
RN  - 0 (ATP Binding Cassette Transporter, Sub-Family B)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (STMN1 protein, human)
RN  - 0 (Stathmin)
RN  - 0 (TUBB3 protein, human)
RN  - 0 (Taxoids)
RN  - 0 (Tubulin)
RN  - 04Q9AIZ7NO (Pemetrexed)
RN  - 15H5577CQD (docetaxel)
RN  - EC 1.14.14.1 (CYP1B1 protein, human)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP1B1)
RN  - EC 2.1.1.45 (TYMS protein, human)
RN  - EC 2.1.1.45 (Thymidylate Synthase)
SB  - AIM
SB  - IM
MH  - ATP Binding Cassette Transporter, Sub-Family B/analysis/drug effects
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/administration & dosage/*therapeutic use
MH  - Chemoradiotherapy/methods
MH  - Cytochrome P-450 CYP1B1/analysis/drug effects
MH  - Feasibility Studies
MH  - Female
MH  - Gene Targeting/*methods
MH  - Genetic Testing/*methods
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Patient Selection
MH  - Pemetrexed/administration & dosage
MH  - Prospective Studies
MH  - Salivary Gland Neoplasms/genetics/*therapy
MH  - Stathmin/analysis/drug effects
MH  - Taxoids/administration & dosage
MH  - Thymidylate Synthase/analysis/drug effects
MH  - Tubulin/analysis/drug effects
MH  - Young Adult
PMC - PMC5944525
EDAT- 2018/04/29 06:00
MHDA- 2018/05/08 06:00
CRDT- 2018/04/29 06:00
PHST- 2018/04/29 06:00 [entrez]
PHST- 2018/04/29 06:00 [pubmed]
PHST- 2018/05/08 06:00 [medline]
AID - 10.1097/MD.0000000000010564 [doi]
AID - 00005792-201804270-00077 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Apr;97(17):e0564. doi: 10.1097/MD.0000000000010564.